MAP2K7 and neurofibromatosis type 1: Selumetinib, a MAPK kinase (MEK) inhibitor, was approved by the FDA in April 2020 for the treatment of children with neurofibromatosis type 1 (NF1)-related symptomatic plexiform neurofibroma (Gross et al., 2020).